Direct-to-Drug Screening Tool Allows for Precision Medicine in Multiple Myeloma
An assay from Mayo Clinic researchers screens multiple myeloma drugs to see how cells with different biomarkers and pretreatment histories react.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19. -
Early-Memory T-Cell Population May Predict CAR-T Efficacy in Several Hematological Malignancies
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM. -
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing. -
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Addition of Isatuximab to Kd Deepens Responses and Extends PFS in R/R Multiple Myeloma
Risk of Thrombosis With Treatments for Newly Diagnosed Multiple Myeloma
Ixazomib Found Effective as a Maintenance Therapy in Patients With Newly Diagnosed MM Who Are Ineligible for Transplant
Characteristics of Ruxolitinib Discontinuation Syndrome in Myelofibrosis
All Oral Proteasome Inhibitor-Containing Regimen in Transplant-Ineligible Multiple Myeloma
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
